Bioadaptives Financials
This page shows Bioadaptives (BDPT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
BioAdaptives runs as a financing-supported micro-revenue model, with new cash raising carrying more weight than product sales.
From FY2024 to FY2025, gross margin expanded from31.8% to68.4% , but operating cash burn still roughly doubled, showing that better unit economics did not fix an expense base far larger than the revenue engine. That mismatch is visible in FY2025, when SG&A of$821K overwhelmed gross profit of$12K , so outside funding was supporting overhead rather than scaling a self-funding operation.
The balance sheet remains deeply creditor-heavy: FY2025 ended with liabilities of
Cash flow shows a recurring dependence on financing, not internal generation: FY2025 operating cash flow was
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Bioadaptives's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bioadaptives has an operating margin of -5701.8%, meaning the company retains $-5702 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -4752.5% the prior year.
Bioadaptives's revenue surged 44.3% year-over-year to $18K, reflecting rapid business expansion. This strong growth earns a score of 0/100.
Bioadaptives's current ratio of 0.09 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
While Bioadaptives generated -$516K in operating cash flow, capex of $18K consumed most of it, leaving -$534K in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Bioadaptives passes 3 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Bioadaptives earns $-14.7 in operating income for every $1 of interest expense (-$1.0M vs $71K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Bioadaptives generated $18K in revenue in fiscal year 2025. This represents an increase of 44.3% from the prior year.
Bioadaptives's EBITDA was -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 73.0% from the prior year.
Bioadaptives earned $-0.15 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 36.4% from the prior year.
Cash & Balance Sheet
Bioadaptives generated -$534K in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 114.0% from the prior year.
Bioadaptives held $215K in cash against $0 in long-term debt as of fiscal year 2025.
Bioadaptives had 12M shares outstanding in fiscal year 2025. This represents a decrease of 99.0% from the prior year.
Margins & Returns
Bioadaptives's gross margin was 68.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 36.6 percentage points from the prior year.
Bioadaptives's operating margin was -5701.8% in fiscal year 2025, reflecting core business profitability. This is down 949.3 percentage points from the prior year.
Capital Allocation
Bioadaptives invested $18K in capex in fiscal year 2025, funding long-term assets and infrastructure.
BDPT Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6K | N/A | $5K+43.9% | $3K | $0 | N/A | $0-100.0% | $675 |
| Cost of Revenue | $1K | N/A | $781-63.8% | $2K | $0 | N/A | $0-100.0% | $246 |
| Gross Profit | $4K | N/A | $4K+262.3% | $1K | $0 | N/A | $0-100.0% | $429 |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $181K | N/A | $251K+26.8% | $198K+38.0% | $143K | N/A | $40K+774.9% | $5K |
| Operating Income | -$198K | N/A | -$266K+4.8% | -$279K-12.1% | -$249K | N/A | -$122K | N/A |
| Interest Expense | $88K | N/A | $14K+46.7% | $10K0.0% | $10K | N/A | $10K-46.0% | $18K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$111K | N/A | -$380K-140.3% | -$158K+19.9% | -$197K | N/A | -$38K | N/A |
| EPS (Diluted) | $-0.01 | N/A | $-0.04-300.0% | $0.02+200.0% | $-0.02 | N/A | $0.00-100.0% | $0.06 |
BDPT Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $136K-39.8% | $226K+81.7% | $124K-54.4% | $273K+146.7% | $110K-57.8% | $262K+464.5% | $46K+431.1% | $9K |
| Current Assets | $123K-41.7% | $212K+94.7% | $109K-57.4% | $256K+131.3% | $110K-57.8% | $262K+464.5% | $46K+431.1% | $9K |
| Cash & Equivalents | $74K-65.8% | $215K+263.1% | $59K-71.9% | $211K+432.3% | $40K-84.9% | $262K+496.6% | $44K+18577.9% | $235 |
| Inventory | $43K-3.9% | $45K+1.1% | $44K+11.8% | $40K-2.5% | $41K+112.3% | $19K | $0-100.0% | $6K |
| Accounts Receivable | N/A | N/A | $590.0% | $59 | N/A | $0 | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.3M-3.6% | $2.4M+48.2% | $1.6M+5.7% | $1.5M-10.6% | $1.7M-2.6% | $1.7M-6.8% | $1.9M-1.3% | $1.9M |
| Current Liabilities | $2.3M-3.6% | $2.4M+48.2% | $1.6M+12.9% | $1.4M-16.3% | $1.7M-2.6% | $1.7M-6.8% | $1.9M-4.1% | $1.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$2.1M-0.3% | -$2.1M-45.4% | -$1.5M-19.0% | -$1.2M+21.6% | -$1.6M-7.3% | -$1.5M+18.9% | -$1.8M+3.3% | -$1.9M |
| Retained Earnings | -$10.8M-1.0% | -$10.7M-8.3% | -$9.9M-4.0% | -$9.5M-1.7% | -$9.4M-2.2% | -$9.2M-4.2% | -$8.8M-0.4% | -$8.8M |
BDPT Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$85K+45.6% | -$156K-3.0% | -$151K-36.3% | -$111K-13.4% | -$98K+2.6% | -$101K-78.4% | -$56K | N/A |
| Capital Expenditures | N/A | $0 | $0 | N/A | N/A | $0 | $0 | N/A |
| Free Cash Flow | N/A | -$156K-3.0% | -$151K | N/A | N/A | -$101K-78.4% | -$56K | N/A |
| Investing Cash Flow | N/A | $0 | $0 | N/A | N/A | $0 | $0 | N/A |
| Financing Cash Flow | N/A | $255K | $0 | N/A | N/A | $194K+94.1% | $100K | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BDPT Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.6% | N/A | 83.1%+50.1pp | 33.0% | N/A | N/A | N/A | 63.6% |
| Operating Margin | -3594.8% | N/A | -5735.9%+2938.1pp | -8674.1% | N/A | N/A | N/A | N/A |
| Net Margin | -2014.6% | N/A | -8193.0%-3287.4pp | -4905.7% | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -81.7% | N/A | -305.2%-247.2pp | -58.0%+120.5pp | -178.5% | N/A | -81.2% | N/A |
| Current Ratio | 0.05-0.0 | 0.09+0.0 | 0.07-0.1 | 0.18+0.1 | 0.07-0.1 | 0.15+0.1 | 0.03+0.0 | 0.00 |
| Debt-to-Equity | -1.06+0.0 | -1.11-0.0 | -1.08+0.1 | -1.22-0.2 | -1.07+0.1 | -1.18-0.2 | -1.03-0.0 | -1.00 |
| FCF Margin | N/A | N/A | -3266.6% | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$2.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Bioadaptives's annual revenue?
Bioadaptives (BDPT) reported $18K in total revenue for fiscal year 2025. This represents a 44.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bioadaptives's revenue growing?
Bioadaptives (BDPT) revenue grew by 44.3% year-over-year, from $13K to $18K in fiscal year 2025.
What is Bioadaptives's EBITDA?
Bioadaptives (BDPT) had EBITDA of -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bioadaptives's gross margin?
Bioadaptives (BDPT) had a gross margin of 68.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bioadaptives's operating margin?
Bioadaptives (BDPT) had an operating margin of -5701.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Bioadaptives's free cash flow?
Bioadaptives (BDPT) generated -$534K in free cash flow during fiscal year 2025. This represents a -114.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bioadaptives's operating cash flow?
Bioadaptives (BDPT) generated -$516K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Bioadaptives's total assets?
Bioadaptives (BDPT) had $226K in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bioadaptives's capital expenditures?
Bioadaptives (BDPT) invested $18K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Bioadaptives's current ratio?
Bioadaptives (BDPT) had a current ratio of 0.09 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Bioadaptives's debt-to-equity ratio?
Bioadaptives (BDPT) had a debt-to-equity ratio of -1.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bioadaptives's cash runway?
Based on fiscal year 2025 data, Bioadaptives (BDPT) had $215K in cash against an annual operating cash burn of $516K. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Bioadaptives's debt-to-equity ratio negative or unusual?
Bioadaptives (BDPT) has negative shareholder equity of -$2.1M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Bioadaptives's Piotroski F-Score?
Bioadaptives (BDPT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Can Bioadaptives cover its interest payments?
Bioadaptives (BDPT) has an interest coverage ratio of -14.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Bioadaptives?
Bioadaptives (BDPT) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.